Current status of immunotherapy for non-small cell lung cancer

Area of Science:

• Oncology
• Immunology
• Translational Medicine

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide, with a critical 5-year survival rate below 15%.
• Conventional treatments for NSCLC have shown limited efficacy due to tumor escape and unique physiological conditions, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review the current landscape of immunotherapies for NSCLC, focusing on their targets, clinical progress, and adverse reactions.
• To provide an overview of emerging immunotherapeutic strategies, including antibody-based therapies and cell therapies, for improved NSCLC treatment.

Main Methods:

• Comprehensive literature review of recent advancements in NSCLC immunotherapy.
• Analysis of clinical progress, targets, and adverse events associated with various immunotherapeutic modalities.

Main Results:

• Immunotherapies, particularly immune checkpoint inhibitors (ICI), have demonstrated significant improvements in overall survival and objective response rates for NSCLC patients.
• Novel approaches like monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, T-cell receptor engineered T cell therapy (TCR-T), and Chimeric antigen receptor T-cell immunotherapy (CAR-T) are expanding treatment options.
• Combination therapies involving these immunotherapeutic agents show promise for enhanced efficacy and overcoming treatment resistance.

Conclusions:

• Immunotherapy represents a paradigm shift in NSCLC treatment, offering more specific and less toxic alternatives to conventional chemotherapy.
• Emerging immunotherapies and their combinations hold significant potential to further improve outcomes for NSCLC patients.
• Continued research into novel targets and therapeutic strategies is crucial for advancing NSCLC care.